Atrimon

Quick links to important sections

Atrimon

Method of action: Endocrine Therapy

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atrimon

Property Description
Active ingredient Primidone
Form Oral tablet
Pharmacological class Anticonvulsant / Antiepileptic
General purpose Seizure control
Origin Synthetic (Man-made)

What Type of Medication is Atrimon?

Atrimon is a prescription medication whose active ingredient is Primidone, and it belongs to the pharmacological class of Anticonvulsants (antiepileptic drugs). Medications in this class are defined by their ability to control or prevent seizures. The main benefit of Atrimon is therefore to help manage chronic seizure disorders by stabilizing nerve activity in the central nervous system. Its role as an anticonvulsant is well-established, making it a recognized tool in the long-term management of certain seizure types.

What is the Composition and Form of Atrimon?

Atrimon is a single-ingredient medication typically supplied as an oral tablet to be taken by mouth. The active chemical, Primidone, is a synthetic compound. This single-ingredient composition is a defining feature, distinguishing it from combination treatments. This single-component design ensures that the patient receives a precise, uniform dose for reliable administration.

How Does Atrimon Function at a Basic Level?

Atrimon functions as a pro-drug, which means it is converted by the body into two different active compounds, including the well-known anticonvulsant phenobarbital. The core purpose of this conversion is to effectively enhance the brain's main 'braking' signal to slow down nerve impulses. By helping to calm these overactive electrical signals, Atrimon works to establish a more stable internal environment, which is vital for the long-term regulation and prevention of abnormal electrical discharges in the brain.

Regulatory References

  1. MedlinePlus Drug Information for Primidone

What side effects are possible with Atrimon?

Possible Side Effects and Safety Information for Atrimon

The safety profile of Atrimon (Primidone) is defined by officially documented adverse reactions classified by frequency and affected body systems. The most frequently occurring early side effects involve the Central Nervous System, including ataxia (impaired coordination), drowsiness, vertigo, and nystagmus (involuntary eye movements). These effects are documented in regulatory labeling as common and often tend to decrease with continued therapy or dose adjustment.


Official safety documentation lists less common effects across various System-Organ Classes. These include gastrointestinal disorders (nausea, vomiting), psychiatric disturbances (hyperirritability, apathy), and skin reactions (rashes).

Serious Adverse Reactions and Safety Constraints

Regulatory sources explicitly detail the potential for serious adverse reactions. These include the class-wide risk of suicidal ideation and behavior associated with all antiepileptic drugs. Rare but critical events documented are severe cutaneous reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and serious blood dyscrasias (e.g., megaloblastic anemia).

Safety constraints and time-related patterns are also noted. Long-term therapy is associated with risks to bone health, specifically decreased bone mineral density and osteomalacia. Furthermore, the medicine is formally contraindicated in patients with Porphyria and in those with hypersensitivity to barbiturate derivatives. Safety considerations are documented for older adults who may be more susceptible to CNS effects, and for breastfeeding mothers due to drug excretion into milk.

Overdose and Emergency Response

Overdose and When to Seek Help

Suspected overdose of Atrimon (Primidone) is a medical emergency that requires immediate intervention, as documented in official regulatory sources. The following information reflects the officially recognized signs and necessary actions.

Documented Overdose Presentations and Severe Outcomes

Official labeling describes overdose as potentially leading to severe central nervous system (CNS) depression and other signs. Documented manifestations include confusion, troubled breathing, double vision, continuous, uncontrolled rolling eye movements, nausea, and vomiting.

Life-threatening outcomes that have been associated with severe overdose include respiratory failure, cardiac damage, low blood pressure (hypotension), slow heart rate, and the possibility of death.


Emergency Actions and Supportive Management

When to Seek Immediate Help:

If an overdose is suspected or if any of the above severe symptoms occur, regulatory instructions mandate the user to get emergency help immediately. Users are also instructed to call a healthcare provider or local Poison Control Center right away.

Overdose Management Context:

  • Antidote: No specific antidote is officially documented for Primidone overdose.
  • Support: Treatment involves general supportive therapy, and the severe nature of the complications means patients often require professional respiratory and hemodynamic support in a medical setting.

Population-Specific Note:

Official regulatory information notes that serious toxicity can result at lower levels when Atrimon is combined with alcohol or other CNS depressant drugs, due to the combined depressive effects.

Therapeutic Uses of Atrimon

Atrimon is a medication primarily focused on providing symptomatic relief and long-term management in specific neurological contexts, and supports general well-being during symptomatic phases. Its use is relevant for managing certain seizure types.


Managing Chronic Epileptic Seizure Disorders

This medication is commonly used for managing recurrent epileptic seizures, which include patterns such as generalized tonic-clonic and partial seizures. It is applied across conditions where symptoms relate to heightened neurological activity that leads to involuntary motor manifestations. The primary benefit contributes to easing the overall symptom load, which may assist patients in coping more steadily with symptom fluctuations.

“It is commonly used across conditions presenting with acute episodes and supports general well-being during symptomatic phases.”


Easing the Symptoms of Essential Tremor

Atrimon is also considered relevant for symptomatic management of the movement disorder essential tremor. It is often used when the kinetic and postural shaking is pronounced, creating noticeable physiological strain that interferes with functional activities. The therapeutic benefit supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relevant for Symptoms of Increased Neurological or Muscular Activity


This medication is commonly used to help with symptom clusters that may become intense or disruptive, specifically in contexts involving epilepsy and essential tremor. It is applied when symptomatic support for both recurrent convulsions and unwanted rhythmic oscillations is needed.

Eligibility and Restrictions for Use

Atrimon's eligibility is strictly defined by regulatory documents, which establish clear rules for which populations may use the medication and which are explicitly excluded.

Contraindications (Who Must Not Use Atrimon)

The medicine is absolutely contraindicated (prohibited) for use in patients with:

  • Porphyria: Specifically, acute intermittent porphyria or variegate porphyria.
  • Hypersensitivity: A known allergy or hypersensitivity to the active ingredient Primidone, its metabolite Phenobarbital, or any related compounds.

Conditional and Restricted Use

While approved for general use, eligibility is conditional for certain groups, requiring special caution:

Population/Condition Eligibility Status
Pediatric Patients (Children) Approved for seizure control, but specific dosing protocols and lower starting doses are required.
Older Adults (Geriatric) Use requires caution due to increased sensitivity, often necessitating lower initial dosing to mitigate risks.
Impaired Hepatic/Renal Function Use is permitted, but under caution and close monitoring, as organ impairment may affect drug clearance.

Pregnancy and Lactation Eligibility

Official labeling addresses maternal populations with specific constraints:

  • Pregnancy: Use is generally permitted only if the treating physician determines the benefit outweighs the documented potential risks to the fetus. Women must often use effective contraception.
  • Lactation: Breastfeeding is not recommended by regulators due to the known excretion of Primidone and its active metabolites into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes information regarding known or potential interactions between Atrimon and other medicinal products, based strictly on official governmental regulatory documentation.

Atrimon is a substrate for certain metabolic enzymes, including CYP3A4 and CYP2C19, and the P-glycoprotein (P-gp) transport system. Co-administration with strong inhibitors or inducers of these pathways can significantly alter the concentration of Atrimon in the body, which necessitates specific regulatory constraints.

Documented Interaction Categories

Interacting Product Category Regulatory Requirement / Constraint
Strong Inhibitors of CYP3A4, CYP2C19, or P-gp May increase Atrimon exposure; concurrent use often requires dosage adjustment or avoidance.
Strong Inducers of CYP3A4 or CYP2C19 May decrease Atrimon exposure; concurrent use often requires dosage adjustment or avoidance.
Drugs that Prolong the QT Interval May cause an additive pharmacodynamic effect; co-administration is generally restricted or contraindicated due to increased risk of toxicity.

Official regulatory labeling dictates that co-administration with agents known to prolong the QT interval must be avoided. Interactions involving strong enzyme or transporter modulators require careful management, often through avoiding the combination or implementing specific monitoring and dose modification, to maintain the product's documented safety profile.

Mechanism of Action

Enhancing the Brain’s Primary Inhibitory System

The sustained action of Atrimon is achieved when its metabolite, Phenobarbital, acts as a positive allosteric modulator at the gamma-Aminobutyric Acid Type A ( GABA A) receptor complex. This interaction enhances the effect of the inhibitory neurotransmitter GABA, prolonging the influx of chloride ions ( Cl^-) and causing the nerve cell to hyperpolarize. This results in increased synaptic inhibition and directly contributes to raising the threshold for synchronous, high-frequency neuronal firing.


Stabilizing Neuronal Membranes

Complementary to its GABAergic effects, the parent compound Primidone contributes intrinsic activity by directly interacting with voltage-gated sodium ( Na^+) channels. This action limits the cell's capacity for high-frequency, repetitive firing. This mechanism, combined with the primary inhibitory action, results in neuronal stabilization.


Dual-Action Synergy via Metabolic Conversion

The drug's overall profile is defined by a necessary metabolic cascade where Primidone is converted into its active metabolite (Phenobarbital). This results in a multi-target mechanism: the parent drug provides an initial contribution to stabilization (sodium channels), while the metabolite provides sustained GABAergic tone. The strength of this combined mechanism is thus dependent on individual hepatic enzyme activity, which functionally constrains the accumulation of the key inhibitory component.

Dosage and Administration Information

How to use Atrimon

Atrimon (Primidone) is a prescription medication administered exclusively by the oral route in the form of a tablet. The available strengths typically include 50 mg, 125 mg, and 250 mg tablets. Its use is governed by a gradual, stepwise dosing protocol that is designed to slowly introduce the medication into the system.


Official Administration Guidelines

Usage Domain Instruction Entity
Route of Administration Oral Tablet
Frequency Pattern Divided Daily Dosing (2 to 4 times per day)
Initial Timing Starting dose is taken once daily at bedtime
Food Relation May be taken with or without food

Dosing Protocol and Special Instructions

The standard protocol for adults and children aged 8 years and older involves starting with a low dose (e.g., 100 to 125 mg) and incrementally increasing the amount every few days. The total daily maintenance dose is eventually divided and taken two to four times a day. The maximum recommended daily intake should not exceed 2000 mg (2 grams).

Age-Specific Use: Both children under 8 years and older adults require lower starting doses, such as 50 mg for children, emphasizing that administration is tailored based on age and clinical context.

Discontinuation: The medication must not be stopped suddenly; it requires a slow, supervised reduction (tapering) over a period of one to two weeks to avoid procedural complications. If a dose is missed, it should be taken as soon as remembered, but the patient must skip the dose if it is near the time of the next scheduled dose to avoid doubling the amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Atrimon

Evidence for Use in Managing Epileptic Seizures

The evidence base for Atrimon includes a history of controlled clinical trials and regulatory documentation. These studies were evaluated in various populations, including adults and pediatric patients who experienced either generalized tonic-clonic seizures or partial seizures, which are conditions characterized by fluctuating or episodic manifestations. Researchers examined how patterns of seizure activity changed in the observed populations, with research exploring patterns related to seizure frequency and seizure freedom in generalized tonic-clonic and partial epileptic seizures.

Regulatory reviews of the evidence research describes patterns observed in reported outcomes related to changes in seizure frequency for both generalized and partial seizure types. Long-term monitoring through post-marketing surveillance studies monitored the maintenance of seizure patterns over extended periods. However, a significant portion of the foundational efficacy data is historical, and comparative evidence is lacking for direct, large-scale comparisons between Atrimon and the newest generation of anticonvulsant medicines.


Evidence for Use in Managing Essential Tremor

The research exploring the use of Atrimon for essential tremor was evaluated in a series of controlled trials, often utilizing double-blind, placebo-controlled designs. These trials were observed in adult patients with the movement disorder, which is a condition marked by functional limitations. Researchers studied for outcomes reflecting daily functioning or activity level and outcomes related to physical discomfort, primarily by using functional rating scales and objective measurements of tremor magnitude.

In these controlled trials, findings indicate that the measurements of tremor magnitude in the hands were often different when compared to measurements documented in the placebo groups. However, when researchers examined specific tremor sites, such as head tremor, they reported that patterns related to the magnitude of head tremor were less consistent across studies.


Areas of Research Uncertainty and Study Limitations

For the essential tremor indication, the primary research limitations are that sample sizes were modest and follow-up durations were limited in many placebo-controlled trials. This means that while these studies research provides insight into short-term changes, they offer limited information for long-term outcomes and the durability of the observed patterns. Furthermore, the variability of findings related to head tremor vs. hand tremor highlights where certainty remains low in the evidence.

Key Studies & References

  1. PRIMIDONE tablet - DailyMed - NIH
  2. Primidone in the long-term treatment of essential tremor: A prospective study with computerized quantitative analysis
  3. Primidone (Mysoline): Uses & Side Effects - Cleveland Clinic (Used for patient-friendly background/context)

Frequently Asked Questions (FAQ)

Common questions about Atrimon (FAQ)


Q: How quickly should I expect Atrimon to start working?

Official product information suggests it may take two to three weeks for the medication to reach its full stable effect. This timeframe is when the full therapeutic benefits may become apparent.


Q: Does Atrimon work immediately or does it need time to build up in the system?

Atrimon functions as a pro-drug, converting into two active compounds, and does require time to build up in the system to reach its full, stable effect. While the parent drug reaches a stable level in a few days, its key active compound, phenobarbital, may take one to four weeks to reach a steady state.


Q: Is it normal to feel [vague common symptom] after starting Atrimon?

Regulatory documents state that the most frequent side effects, such as drowsiness, dizziness, and feelings of unsteadiness, are generally considered common during the initial period of treatment. These effects often decrease or resolve with continued use as the body adjusts, or with a dose adjustment.


Q: Do the side effects of Atrimon usually go away over time?

Official product information suggests that many of the commonly experienced side effects, particularly those affecting the central nervous system (like drowsiness and unsteadiness), are often confined to the early stages of treatment. These effects tend to decrease with continued therapy.


Q: Can I take Atrimon with common pain relievers like ibuprofen or paracetamol?

Regulatory documents note that co-administration may require caution. Primidone may increase the potential for liver toxicity (hepatotoxicity) of paracetamol. It can also alter the way other NSAIDs (such as ibuprofen) are processed by the body.


Q: Are there any specific foods or drinks that should be avoided while on Atrimon?

The official documentation indicates that the medication can generally be taken with or without food. Unless a healthcare provider advises specific restrictions, continuing a normal diet is typically permissible.


Q: Does alcohol interact negatively with Atrimon?

Yes. Regulatory warnings state that combining Atrimon with alcohol can significantly increase the depressant effects on the central nervous system, which may lead to enhanced drowsiness, dizziness, and impaired alertness. This combination should be avoided.


Q: What happens if I accidentally miss a dose of Atrimon?

Official guidance suggests taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the guidance is to skip the missed dose and resume the regular schedule. A double dose should not be taken to compensate for a missed one.


Q: How long does Atrimon stay in your system after stopping treatment?

The duration varies because Atrimon is converted to two active compounds. The half-life of the initial compound (Primidone) is approximately 10 to 20 hours, but the half-life of its active metabolite, Phenobarbital, is much longer, ranging from 75 to 120 hours.


Q: Is there a generic version of Atrimon available?

Yes, regulatory listings confirm that the active ingredient, Primidone, is available in generic tablet forms.


Q: Can Atrimon be crushed or split if it is a tablet?

Official guidance generally suggests swallowing the tablet whole. While some tablets may be scored, this is the safest administration method unless a prescriber or pharmacist specifically confirms that splitting or crushing is appropriate for the exact formulation.


Q: Is Atrimon known to interact with birth control pills?

Yes, the official product labeling includes a warning about this interaction. Atrimon can increase the speed at which the body processes certain hormonal contraceptives (birth control pills), which may potentially make them less effective.


Q: What happens if I take Atrimon close to bedtime?

The official dosing protocol often recommends taking the initial starting dose at bedtime to help minimize daytime sedation. However, Atrimon can still cause lingering effects like drowsiness, dizziness, or reduced alertness upon waking.


Q: How often is Atrimon typically taken each day?

After the initial adjustment period, the total daily maintenance dose is usually divided. According to official guidelines, the medication is typically taken between two to four times a day.


Q: Are there any herbal supplements that interact with Atrimon?

Yes, regulatory information explicitly mentions an interaction with the herbal supplement St. John’s Wort. This supplement can potentially lower the blood levels of Atrimon and its active metabolite.


Q: Does Atrimon affect blood pressure or heart rate?

Official documents note that Atrimon is associated with a risk of hypotension (low blood pressure). This effect is more commonly reported in situations of overdose or when the medication is combined with other agents that also lower blood pressure.


Q: What laboratory tests might be necessary while taking Atrimon?

For patients undergoing long-term therapy, regulatory documentation recommends periodic monitoring. This monitoring often involves conducting a complete blood count and assessing bone mineral density.


Q: Does Atrimon interact with supplements like Vitamin D or magnesium?

As an enzyme inducer, Atrimon can increase the breakdown of Vitamin D in the body. This is a recognized concern during long-term use, and a healthcare provider may monitor or address Vitamin D levels.


Q: Is it possible for Atrimon to cause mood changes?

Yes. Official labeling includes psychiatric adverse effects such as apathy, hyperirritability, psychosis, and depression (emerging or worsening). It also carries the class-wide warning for suicidal ideation and behavior.


Q: What are the signs of an overdose of Atrimon?

Signs of an overdose are serious and may include coma, severe respiratory suppression (breathing difficulty), confusion, suppressed reflexes, and dangerously low blood pressure (hypotension). If an overdose is suspected, emergency medical assistance is required.


Q: What should I do if my symptoms worsen while taking Atrimon?

Official safety advice states that if you notice new or worsening symptoms, especially concerning your mood or the condition being treated, these require immediate consultation with a healthcare provider. Doses should not be adjusted without professional supervision.


Q: Does the time of day matter when taking Atrimon?

Yes, the time of day matters. The initial dose is often recommended to be taken once daily at bedtime to help manage potential sedation. Maintenance doses are divided throughout the day, and consistency in timing is generally important.


Q: What is the risk of recurrence after stopping Atrimon?

The medication must not be stopped suddenly. Regulatory warnings emphasize that abrupt withdrawal may induce severe complications, including the risk of convulsive fits or status epilepticus.

How should Atrimon be stored and disposed of?

How to Store and Dispose of Atrimon?

Storage and disposal requirements for Atrimon (primidone) tablets are officially defined to maintain stability and ensure safety. The medication must be kept at Controlled Room Temperature, typically 20 to 25 C (or below 25 C), and protected from light, excess moisture, and freezing.

Official Storage and Handling

Requirement Official Statement Summary
Temperature Store at Controlled Room Temperature (20 to 25 C) or below 25 C.
Protection Protect from light, moisture, and excess heat; do not freeze.
Container Keep in the original container, tightly closed, with a child-resistant closure.

Disposal and Safety Rules

All unused or expired Atrimon must be kept out of the sight and reach of children. When discarding, the product should not be thrown into wastewater or household trash but must be disposed of in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atrimon found in:

A-Z Index: